Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 3/20 | 0.40 |
| ▸ | RARG | P13631 | 3/20 | 0.40 |
| ▸ | RARB | P10826 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 5/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742798 | 0.91 | MAPT (0.39) | RARARARGRARBALOX5NR1H4 | |
| SCHEMBL4556762 | 0.83 | CYP2D6 (0.42) | RARARARGRARBALOX5ALDH1A1 | |
| SCHEMBL12946430 | 0.80 | ALOX5 (0.43) | RARARARGRARBALOX5NR1H4 | |
| SCHEMBL2328053 | 0.78 | ALOX5 (0.41) | ALOX5NR1H4PTGS2ROR1MAOB | |
| SCHEMBL949460 | 0.77 | MAOB (0.51) | ALOX5MAOBMAOAALDH1A1MAPT | |
| SCHEMBL4549088 | 0.77 | MAOB (0.35) | ALOX5NR1H4MAOBMAOAALDH1A1 | |
| SCHEMBL4556779 | 0.77 | THRA (0.37) | ALOX5NR1H4PTPN1ROR1MAOB | |
| SCHEMBL1962780 | 0.75 | MAOB (0.51) | ALOX5MAOBMAOAALDH1A1MAPT | |
| SCHEMBL952469 | 0.73 | NR1H4 (0.54) | RARARARGRARBALOX5NR1H4 | |
| SCHEMBL2071380 | 0.72 | RARA (0.48) | RARARARGRARBALOX5NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103641808-B | The enantioselective hydrogenation method of chromene | GIRINDUS AMERICA INC. (US) | 2016-04-20 | — | — | CN | disclosed |
| CN-103755675-B | The enantioselective hydrogenation method of chromene | GIRINDUS AMERICA INC. (US) | 2015-11-18 | — | — | CN | disclosed |
| EP-1919887-B1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA INC (US) | 2015-02-18 | — | — | EP | disclosed |
| CN-101535286-B | Process for the enantioselective hydrogenation of chromenes | GIRINDUS AMERICA INC | 2014-05-07 | — | — | CN | disclosed |
| US-8716497-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716497-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-05-06 | — | — | US | disclosed |
| CN-103755675-A | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA INC | 2014-04-30 | — | — | CN | disclosed |
| CN-103641808-A | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA INC | 2014-03-19 | — | — | CN | disclosed |
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20100069653-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | Children hospital medical center (US) | 2010-03-18 | — | — | US | disclosed |
| CN-101535286-A | Process for the enantioselective hydrogenation of chromenes | GIRINDUS AMERICA INC (US) | 2009-09-16 | — | — | CN | disclosed |
| US-7528267-B2 | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528267-B2 | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528267-B2 | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1919887-A2 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | Girindus America, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007016423-A2 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | AUSIO PHARMACEUTICALS, LLC | 2007-02-01 | — | — | US | disclosed |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | AUSIO PHARMACEUTICALS, LLC | 2007-02-01 | — | — | US | disclosed |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | AUSIO PHARMACEUTICALS, LLC | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | RARA 2242/4885RARG 1393/4885RARB 2733/4885 |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | HRH3, HRH2, CHD8 | RARA 2242/4885RARG 1393/4885RARB 2733/4885 |
| US-20100069653-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | RARA 2242/4885RARG 1393/4885RARB 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.